Agreement brings IFA test kits and instruments to the US

Aesku.Group, (Wendelsheim, Germany), a leading provider of innovative diagnostic solutions, has signed an exclusive distribution agreement with laboratory industry provider Thermo Fisher Scientific, for the marketing, sales and support of its range of FDA-Cleared immunofluorescence (IFA) products, automated instruments and software in the United States. The gives customers access to autoimmune diagnostics and automated instrumentation, complimenting both the EliA™ autoimmune testing portfolio and Phadia™ laboratory instruments with Aesku IFA testing and Helios® HTC systems.
"Our partnership with Aesku underscores our commitment to enabling our customers to make the world healthier by providing innovative solutions that help advance the detection and diagnosis of complex autoimmune diseases," stated Santhosh Nair, president of ImmunoDiagnostics, Thermo Fisher Scientific. “Aesku has pioneered innovative and efficient solutions that synergise seamlessly with our existing portfolio. We are excited about offering these solutions to our customers and the opportunity to positively impact more patient lives.”
Dr. Torsten Matthias, President and founder of Aesku, said “we are thrilled to enter this partnership with Thermo Fisher Scientific, a global diagnostics powerhouse, to bring our pioneering IFA solutions to the forefront of the US market. Aesku's commitment to innovation in autoimmune diagnostics aligns seamlessly with Thermo Fisher's Mission of enabling customers to make the world healthier, cleaner and safer. Together, we are setting new benchmarks for accuracy and efficiency in autoimmunity testing, ensuring clinicians and patients receive the most advanced diagnostic capabilities available.”

More information online